{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:07:19Z","timestamp":1788826039930,"version":"build-2803163510"},"reference-count":146,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clinthera.2023.01.004","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T06:30:34Z","timestamp":1675233034000},"page":"162-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Role of Colchicine in Different Clinical Phenotypes of Behcet Disease"],"prefix":"10.1016","volume":"45","author":[{"given":"Zeyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5530-5624","authenticated-orcid":false,"given":"Yao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.01.004_bib0001","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2040622314523062","article-title":"Update on the therapy of Behcet disease","volume":"5","author":"Saleh","year":"2014","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0002","doi-asserted-by":"crossref","first-page":"19454","DOI":"10.1021\/jacs.1c08659","article-title":"Total Biosynthesis of the Tubulin-Binding Alkaloid Colchicine","volume":"143","author":"Nett","year":"2021","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0003","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1038\/s41598-017-06005-5","article-title":"NMR and DFT investigations of structure of colchicine in various solvents including density functional theory calculations","volume":"7","author":"Pierens","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0004","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.amjmed.2014.12.010","article-title":"Colchicine: old and new","volume":"128","author":"Slobodnick","year":"2015","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0005","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/art.1780340806","article-title":"Long-term colchicine treatment in children with familial Mediterranean fever","volume":"34","author":"Zemer","year":"1991","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0006","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0049-0172(91)90019-V","article-title":"Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years","volume":"20","author":"Ben-Chetrit","year":"1991","journal-title":"Seminars In Arthritis and Rheumatism"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1568010053622984","article-title":"Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update","volume":"4","author":"Cerquaglia","year":"2005","journal-title":"Current Drug Targets. Inflammation and Allergy"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0008","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jama.2015.12763","article-title":"Evaluation and Treatment of Pericarditis: A Systematic Review","volume":"314","author":"Imazio","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0009","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.15896","article-title":"Colchicine: an ancient drug with novel applications","volume":"178","author":"Dasgeb","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0010","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10787-020-00701-x","article-title":"Effect of combined colchicine-corticosteroid treatment on neutrophil\/lymphocyte ratio: a predictive marker in Beh\u00e7et disease activity","volume":"28","author":"Djaballah-Ider","year":"2020","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0011","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13075-021-02615-7","article-title":"Epidemiology and treatment of Beh\u00e7et's disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions","volume":"23","author":"Hammam","year":"2021","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0012","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.2174\/1381612826666201023144320","article-title":"Colchicine: An Ancient Drug with Multiple Benefits","volume":"27","author":"El Hasbani","year":"2021","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0013","first-page":"808","article-title":"2018 update of the EULAR recommendations for the management of Behcet's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12969-017-0162-4","article-title":"Intestinal Behcet and Crohn's disease: two sides of the same coin","volume":"15","author":"Valenti","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0015","doi-asserted-by":"crossref","first-page":"iii101","DOI":"10.1093\/rheumatology\/kez626","article-title":"Behcet: the syndrome","volume":"59","author":"Bettiol","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0016","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00002281-200401000-00008","article-title":"Beh\u00e7et syndrome","volume":"16","author":"Yurdakul","year":"2004","journal-title":"Current opinion in rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0017","first-page":"148","article-title":"Beh\u00e7et's syndrome: disease manifestations, management, and advances in treatment: nature clinical practice","volume":"3","author":"Yazici","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0018","first-page":"1689","article-title":"Beh\u00e7et's disease in southern Chinese patients","volume":"29","author":"Mok","year":"2002","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0019","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.22500","article-title":"Epidemiology and clinical course of Beh\u00e7et's disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study","volume":"57","author":"Salvarani","year":"2007","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0020","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2133.2007.08116.x","article-title":"Clinical features and natural course of Beh\u00e7et's disease in 661 cases: a multicentre study","volume":"157","author":"Alpsoy","year":"2007","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0021","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/09273948.2012.723112","article-title":"Epidemiology of Behcet disease","volume":"20","author":"Khairallah","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0022","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12882-017-0451-7","article-title":"A novel case of renal pathergy reaction in a Beh\u00e7et's disease patient complicated by IgA vasculitis","volume":"18","author":"Higashihara","year":"2017","journal-title":"BMC Nephrology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0023","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaut.2015.08.013","article-title":"The immunogenetics of Beh\u00e7et's disease: a comprehensive review","volume":"64","author":"Takeuchi","year":"2015","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s13317-016-0074-1","article-title":"Beh\u00e7et's disease physiopathology: a contemporary review","volume":"7","author":"Zeidan","year":"2016","journal-title":"Auto-Immunity Highlights"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0025","first-page":"128","article-title":"Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bech\u00e7et's disease; soluble TNFR-75 as a biological marker of disease activity","volume":"24","author":"Turan","year":"1997","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0026","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cyto.2008.10.007","article-title":"Interleukin-6 in neuro-Beh\u00e7et's disease: association with disease subsets and long-term outcome","volume":"44","author":"Akman-Demir","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0027","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000018426","article-title":"Adamantiades-Beh\u00e7et's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate","volume":"201","author":"Katsantonis","year":"2000","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0028","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00296-005-0029-8","article-title":"Serum interleukin-18 levels in patients with Beh\u00e7et's disease: is its expression associated with disease activity or clinical presentations?","volume":"26","author":"Musabak","year":"2006","journal-title":"Rheumatology International"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0029","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-4632.2009.03905.x","article-title":"Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement","volume":"48","author":"Durmazlar","year":"2009","journal-title":"International Journal of Dermatology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0030","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1177\/112067210901900616","article-title":"Inflammatory mediators and posterior segment involvement in ocular Behcet disease","volume":"19","author":"Ozdamar","year":"2009","journal-title":"European Journal of Ophthalmology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102763","article-title":"Interleukin 1\u03b1: a comprehensive review on the role of IL-1\u03b1 in the pathogenesis and treatment of autoimmune and inflammatory diseases","volume":"20","author":"Cavalli","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0032","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIRCULATIONAHA.115.017738","article-title":"Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Beh\u00e7et disease","volume":"133","author":"Becatti","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0033","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fimmu.2019.00665","article-title":"Immunopathogenesis of Behcet's disease","volume":"10","author":"Tong","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0034","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jdermsci.2018.08.010","article-title":"Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Beh\u00e7et's disease","volume":"92","author":"Safi","year":"2018","journal-title":"Journal of Dermatological Science"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0035","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/art.24642","article-title":"HLA-B51\/B5 and the risk of Beh\u00e7et's disease: a systematic review and meta-analysis of case-control genetic association studies","volume":"61","author":"de Menthon","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0036","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5072582","article-title":"Update on vertigo in autoimmune disorders, from diagnosis to treatment","volume":"2018","author":"Girasoli","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0037","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","article-title":"Behcet syndrome: a contemporary view","volume":"14","author":"Yazici","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0038","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/ard.60.11.996","article-title":"Beh\u00e7et's disease: infectious aetiology, new autoantigens, and HLA-B51","volume":"60","author":"Direskeneli","year":"2001","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0039","doi-asserted-by":"crossref","first-page":"64263","DOI":"10.18632\/oncotarget.19500","article-title":"Aberrant DNA methylation of GATA binding protein 3 (GATA3), interleukin-4 (IL-4), and transforming growth factor-\u03b2 (TGF-\u03b2) promoters in Behcet's disease","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0040","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/14397595.2016.1218595","article-title":"Genome-wide DNA methylation patterns in CD4+ T cells from Chinese Han patients with rheumatoid arthritis","volume":"27","author":"Guo","year":"2017","journal-title":"Modern Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0041","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/08916930802024145","article-title":"Epigenetics and T-cell immunity","volume":"41","author":"Sawalha","year":"2008","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0042","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3389\/fimmu.2019.02830","article-title":"Treating the different phenotypes of Beh\u00e7et's syndrome","volume":"10","author":"Bettiol","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0043","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s11739-019-02046-y","article-title":"Phenotypes in Beh\u00e7et's syndrome","volume":"14","author":"Seyahi","year":"2019","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0044","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0045","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.27568","article-title":"Mortality in Beh\u00e7et's disease","volume":"62","author":"Saadoun","year":"2010","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.reuma.2019.03.002","article-title":"Quality of life in patients with Beh\u00e7et disease and its relation with clinical symptoms and disease activity","volume":"17","author":"Khabbazi","year":"2021","journal-title":"Reumatologia Clinica"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0047","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41572-021-00301-1","article-title":"Beh\u00e7et syndrome","volume":"7","author":"Yazici","year":"2021","journal-title":"Nature Reviews Disease Primers"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0048","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjmed.2004.05.027","article-title":"Pulmonary artery aneurysms in Beh\u00e7et syndrome","volume":"117","author":"Hamuryudan","year":"2004","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0049","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/JMDH.S93681","article-title":"Beh\u00e7et's syndrome: providing integrated care","volume":"10","author":"Esatoglu","year":"2017","journal-title":"J Multidiscip Healthc"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0050","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/1381612824666180123110042","article-title":"Colchicine pharmacokinetics and mechanism of action","volume":"24","author":"Angelidis","year":"2018","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0051","unstructured":"Colchicine. U.S. Food and Drug Administration website, 2009 [updated 2009 Jul: cited 2022 Jun 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022351lbl.pdf."},{"key":"10.1016\/j.clinthera.2023.01.004_bib0052","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3904\/kjim.2016.131","article-title":"Effects of colchicine on renal fibrosis and apoptosis in obstructed kidneys","volume":"33","author":"Kim","year":"2018","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0053","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.3748\/wjg.v16.i23.2889","article-title":"Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease","volume":"16","author":"Muntoni","year":"2010","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0054","first-page":"6269","article-title":"Anticancer effects of colchicine on hypopharyngeal cancer","volume":"37","author":"Cho","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000182257","article-title":"Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Beh\u00e7et's disease","volume":"218","author":"K\u00f6se","year":"2009","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0056","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000246336","article-title":"Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Beh\u00e7et's disease","volume":"192","author":"Calg\u00fcneri","year":"1996","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0057","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1517\/17425255.2015.1076391","article-title":"Colchicine as an anti-inflammatory and cardioprotective agent","volume":"11","author":"Gasparyan","year":"2015","journal-title":"Expert Opinion On Drug Metabolism & Toxicology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0058","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40261-014-0238-6","article-title":"Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease","volume":"34","author":"Wason","year":"2014","journal-title":"Clinical Drug Investigation"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0059","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/00365529409094847","article-title":"Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment","volume":"29","author":"Rudi","year":"1994","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0060","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/j.1552-4604.1996.tb04753.x","article-title":"Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses","volume":"36","author":"Ferron","year":"1996","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0061","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/15563650.2017.1422510","article-title":"Anti-colchicine Fab fragments prevent lethal colchicine toxicity in a porcine model: a pharmacokinetic and clinical study","volume":"56","author":"Eddleston","year":"2018","journal-title":"Clinical Toxicology (Philadelphia, Pa.)"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0062","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4081\/reumatismo.2013.720","article-title":"Acute colchicine overdose: report of three cases","volume":"65","author":"Aghabiklooei","year":"2014","journal-title":"Reumatismo"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0063","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s11739-021-02654-7","article-title":"Colchicine efficacy and safety for the treatment of cardiovascular diseases","volume":"16","author":"Andreis","year":"2021","journal-title":"Internal and Emergency Medicine"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0064","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/09546634.2019.1690621","article-title":"Efficacy and safety of colchicine in inflammatory skin diseases: a retrospective, monocentric study in a large tertiary center","volume":"32","author":"Anzengruber","year":"2021","journal-title":"Journal of Dermatological Treatment"},{"issue":"suppl","key":"10.1016\/j.clinthera.2023.01.004_bib0065","first-page":"15","article-title":"The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors","volume":"92","author":"Wechalekar","year":"2014","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0066","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12325-012-0028-6","article-title":"Are dosing adjustments required for colchicine in the elderly compared with younger patients?","volume":"29","author":"Wason","year":"2012","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0067","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1749-6632.2009.04674.x","article-title":"Colchicine revisited","volume":"1173","author":"Bhat","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0068","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1073\/pnas.79.22.6753","article-title":"Tubulin bound to colchicine forms polymers different from microtubules","volume":"79","author":"Andreu","year":"1982","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0069","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.40.6.605","article-title":"Prolonged reduction in polymorphonuclear adhesion following oral colchicine","volume":"40","author":"Fordham","year":"1981","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0070","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1172\/JCI118147","article-title":"Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils","volume":"96","author":"Cronstein","year":"1995","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0071","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11926-008-0036-3","article-title":"Colchicine: its mechanism of action and efficacy in crystal-induced inflammation","volume":"10","author":"Nuki","year":"2008","journal-title":"Current Rheumatology Reports"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0072","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/imm.12741","article-title":"Ficolin-A\/2, acting as a new regulator of macrophage polarization, mediates the inflammatory response in experimental mouse colitis","volume":"151","author":"Yang","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0073","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.clinthera.2014.07.017","article-title":"Mechanism of action of colchicine in the treatment of gout","volume":"36","author":"Dalbeth","year":"2014","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0074","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/ni.3457","article-title":"Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS","volume":"17","author":"Park","year":"2016","journal-title":"Nature Immunology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0076","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0077","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.20172222","article-title":"Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity","volume":"215","author":"Boucher","year":"2018","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0078","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.tcm.2020.04.006","article-title":"The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment","volume":"31","author":"Lopalco","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0079","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1476-5381.2011.01254.x","article-title":"Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action","volume":"163","author":"Marques-da-Silva","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0080","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ni.2550","article-title":"Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome","volume":"14","author":"Misawa","year":"2013","journal-title":"Nature Immunology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0081","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.2174\/1568026617666170104145640","article-title":"Microtubule targeting agents as cancer chemotherapeutics: an overview of molecular hybrids as stabilizing and destabilizing agents","volume":"17","author":"Tangutur","year":"2017","journal-title":"Current Topics In Medicinal Chemistry"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0082","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.lfs.2013.07.002","article-title":"Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma","volume":"93","author":"Lin","year":"2013","journal-title":"Life Sciences"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0083","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/529179","article-title":"Pivotal role of AKAP12 in the regulation of cellular adhesion dynamics: control of cytoskeletal architecture, cell migration, and mitogenic signaling","volume":"2012","author":"Akakura","year":"2012","journal-title":"Journal of Signal Transduction"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0084","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1089\/jir.2010.0132","article-title":"Interferon-inducible antiviral protein MxA enhances cell death triggered by endoplasmic reticulum stress","volume":"31","author":"Numajiri Haruki","year":"2011","journal-title":"Journal of Interferon & Cytokine Research"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0085","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1593\/neo.11664","article-title":"Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-\u03b22","volume":"13","author":"Sun","year":"2011","journal-title":"Neoplasia (New York, N.Y.)"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0086","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jss.2007.04.029","article-title":"Colchicine inhibits intimal hyperplasia and leukocyte VEGF expression in dogs","volume":"146","author":"Atta","year":"2008","journal-title":"Journal of Surgical Research"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0087","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/med.20097","article-title":"Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin","volume":"28","author":"Bhattacharyya","year":"2008","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0088","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11060-015-1874-2","article-title":"Colchicine derivative as a potential anti-glioma compound","volume":"124","author":"Fang","year":"2015","journal-title":"Journal of Neuro-oncology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0089","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/ijms20030586","article-title":"The potential of combining tubulin-targeting anticancer therapeutics and immune therapy","volume":"20","author":"Fong","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0090","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nature Medicine"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0091","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41573-019-0040-5","article-title":"Targeting metabolic dysregulation for fibrosis therapy","volume":"19","author":"Zhao","year":"2020","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0092","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: from mechanisms to medicines","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0093","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2011-09-377648","article-title":"Platelet TGF-\u03b21 contributions to plasma TGF-\u03b21, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload","volume":"119","author":"Meyer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0094","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.rmed.2007.02.006","article-title":"Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis","volume":"101","author":"Tzortzaki","year":"2007","journal-title":"Respiratory Medicine"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0095","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ejps.2013.08.004","article-title":"Benefit of combined therapy with nicorandil and colchicine in preventing monocrotaline-induced rat pulmonary arterial hypertension","volume":"50","author":"Lee","year":"2013","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0096","first-page":"F1466","article-title":"Colchicine attenuates renal injury in a model of hypertensive chronic kidney disease","volume":"305","author":"Guan","year":"2013","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0097","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijcard.2019.01.054","article-title":"Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease","volume":"281","author":"Kajikawa","year":"2019","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0098","first-page":"486","article-title":"Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","volume":"7","author":"Samuel","year":"2021","journal-title":"European Heart Journal"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0099","first-page":"778","article-title":"Colchicine in patients with chronic coronary disease: reply","volume":"384","author":"Fiolet","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0100","first-page":"399","article-title":"A double blind study of colchicine in Beh\u00e7et's disease","volume":"65","author":"Aktulga","year":"1980","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0101","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/s10165-009-0200-2","article-title":"Colchicine versus placebo in Beh\u00e7et's disease: randomized, double-blind, controlled crossover trial","volume":"19","author":"Davatchi","year":"2009","journal-title":"Modern Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0102","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Beh\u00e7et's syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0103","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0104","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13075-020-2120-7","article-title":"Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials","volume":"22","author":"Stewart","year":"2020","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0105","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2459\/JCM.0000000000001157","article-title":"Adverse events of colchicine for cardiovascular diseases: a comprehensive meta-analysis of 14\u200a188 patients from 21 randomized controlled trials","volume":"22","author":"Andreis","year":"2021","journal-title":"Journal of Cardiovascular Medicine (Hagerstown, Md.)"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0106","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3389\/fcvm.2021.676771","article-title":"Efficacy and safety of colchicine in post-acute myocardial infarction patients: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Diaz-Arocutipa","year":"2021","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"suppl 127","key":"10.1016\/j.clinthera.2023.01.004_bib0107","first-page":"3","article-title":"One year in review 2020: Beh\u00e7et's syndrome","volume":"38","author":"Hatemi","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0108","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00535-007-2090-4","article-title":"Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach","volume":"42","author":"Kobayashi","year":"2007","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0109","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1600-0714.2009.00774.x","article-title":"Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-alpha level in patients with mucocutaneous type of Behcet's disease","volume":"38","author":"Sun","year":"2009","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0110","first-page":"148","article-title":"Long-term effects of cyclophosphamide and colchicine treatment in Beh\u00e7et's disease","volume":"23","author":"Kazokoglu","year":"1991","journal-title":"Annals of Ophthalmology"},{"issue":"9","key":"10.1016\/j.clinthera.2023.01.004_bib0111","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011018","article-title":"Interventions for the management of oral ulcers in Beh\u00e7et's disease","volume":"2014","author":"Taylor","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0112","doi-asserted-by":"crossref","first-page":"iii108","DOI":"10.1093\/rheumatology\/keaa086","article-title":"Management of Behcet's syndrome","volume":"59","author":"Karadag","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0113","first-page":"1365","article-title":"Recurrent aphthous stomatitis: treatment with colchicine: an open trial of 54 cases [in French]","volume":"129","author":"Fontes","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0114","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/jop.13020","article-title":"Value of colchicine as treatment for recurrent oral ulcers: a systematic review","volume":"49","author":"Cabras","year":"2020","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/BOR.0000000000000666","article-title":"Management of Beh\u00e7et syndrome","volume":"32","author":"Yazici","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0116","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/art.1780391216","article-title":"The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Beh\u00e7et's disease: a randomized clinical trial","volume":"39","author":"Calg\u00fcneri","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0117","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et's disease","volume":"341","author":"Sakane","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0118","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/09273948.2012.665124","article-title":"Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Beh\u00e7et's disease","volume":"20","author":"Takeuchi","year":"2012","journal-title":"Ocular Immunology and Inflammation"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0119","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(77)92945-2","article-title":"Colchicine in Beh\u00e7et's disease","volume":"2","author":"Mizushima","year":"1977","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current concepts in the etiology and treatment of Beh\u00e7et disease","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Survey of Ophthalmology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0121","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","article-title":"The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease: indication of anti-TNF\u03b1 monoclonal antibodies","volume":"49","author":"Hisamatsu","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0126","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00535-004-1560-1","article-title":"Monozygotic twins concordant for intestinal Beh\u00e7et's disease","volume":"40","author":"Kobayashi","year":"2005","journal-title":"Journal of Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0127","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s005950200013","article-title":"Ileal perforation in diffuse intestinal Beh\u00e7et disease: report of a case","volume":"32","author":"Hizawa","year":"2002","journal-title":"Surgery Today"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0128","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/BF02235590","article-title":"Long-term clinical course and prognostic factors in intestinal Beh\u00e7et's disease","volume":"43","author":"Choi","year":"2000","journal-title":"Diseases of the Colon and Rectum"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13075-021-02429-7","article-title":"Cluster analysis of phenotypes of patients with Beh\u00e7et's syndrome: a large cohort study from a referral center in China","volume":"23","author":"Zou","year":"2021","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0130","first-page":"545","article-title":"The effect of colchicine on mean platelet volume in Behcet's disease","volume":"45","author":"Ata\u015f","year":"2015","journal-title":"Annals of Clinical and Laboratory Science"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0131","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00296-019-04452-z","article-title":"Digital ischemia in Beh\u00e7et's disease: case-based review","volume":"40","author":"Hari","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0132","first-page":"124","article-title":"Behcet's disease presenting with life threatening manifestation of cerebral venous thrombosis","volume":"32","author":"Naveed","year":"2020","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0133","doi-asserted-by":"crossref","first-page":"e19814","DOI":"10.1097\/MD.0000000000019814","article-title":"Colchicine therapy for deep vein thrombosis in a patient with vascular-type Behcet disease: a case report","volume":"99","author":"Nonaka","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0134","first-page":"151","article-title":"Cardiac pseudotumor revealing Beh\u00e7et's disease [in French]","volume":"26","author":"Nya","year":"2017","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.bor.0000145520.76348.dd","article-title":"Major vessel involvement in Beh\u00e7et disease","volume":"17","author":"Calamia","year":"2005","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0136","article-title":"Neuro-Behcet's disease: an update on diagnosis, differential diagnoses, and treatment","volume":"39","author":"Borhani-Haghighi","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0137","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s00415-013-7209-3","article-title":"Diagnosis and management of Neuro-Beh\u00e7et's disease: international consensus recommendations","volume":"261","author":"Kalra","year":"2014","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0138","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s004150050205","article-title":"Beh\u00e7et's disease and the nervous system","volume":"245","author":"Serdaro\u011flu","year":"1998","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0139","first-page":"192","article-title":"Neuro-Beh\u00e7et's disease: epidemiology, clinical characteristics, and management. The Lancet","volume":"8","author":"Al-Araji","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0140","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00415-010-5885-9","article-title":"Cerebral venous thrombosis in Beh\u00e7et's disease: a systematic review","volume":"258","author":"Aguiar de Sousa","year":"2011","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0141","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","article-title":"CNS involvement occurs more frequently in patients with Beh\u00e7et's disease under cyclosporin A (CSA) than under other medications\u2013results of a retrospective analysis of 117 cases","volume":"25","author":"K\u00f6tter","year":"2006","journal-title":"Clinical Rheumatology"},{"issue":"12","key":"10.1016\/j.clinthera.2023.01.004_bib0142","article-title":"Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Beh\u00e7et's Syndrome. The Cochrane Database of","author":"Nava","year":"2014","journal-title":"Systematic Reviews"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0143","first-page":"1245","article-title":"Recent aspects of neuro-Behcet's disease [in Japanese]","volume":"65","author":"Hirohata","year":"2013","journal-title":"Shinkei Kenkyu No Shinpo"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0144","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/1756-185X.12265","article-title":"Neuro-beh\u00e7et's disease in South Korea: clinical characteristics and treatment response","volume":"17","author":"Yoon","year":"2014","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0145","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0035-3787(05)85026-X","article-title":"Beh\u00e7et's disease associated with peripheral neuropathy [in French]","volume":"161","author":"Ben Ghorbel","year":"2005","journal-title":"Revue Neurologique"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0146","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1179\/174313208X346134","article-title":"Effects of colchicine on strength-duration properties of sensory and motor axons","volume":"31","author":"Yerdelen","year":"2009","journal-title":"Neurological Research"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0147","first-page":"1050","article-title":"Deaths from intravenous colchicine resulting from a compounding pharmacy error: Oregon and Washington, 2007","volume":"56","year":"2007","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0148","first-page":"665","article-title":"The treatment of chronic recurrent oral aphthous ulcers","volume":"111","author":"Altenburg","year":"2014","journal-title":"Deutsches Arzteblatt International"},{"key":"10.1016\/j.clinthera.2023.01.004_bib0149","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejim.2010.09.010","article-title":"Colchicine in clinical medicine: a guide for internists","volume":"21","author":"Cocco","year":"2010","journal-title":"European Journal of Internal Medicine"}],"updated-by":[{"DOI":"10.1016\/j.clinthera.2023.06.020","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000}}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823000243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823000243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T03:38:35Z","timestamp":1697081915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823000243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":146,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0149291823000243"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.01.004","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.clinthera.2023.06.020","asserted-by":"object"}]},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Colchicine in Different Clinical Phenotypes of Behcet Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}